Title
SARS-CoV-2 infections in households in a peri-urban community of Lima, Peru: A prospective cohort study
Date Issued
01 May 2022
Access level
open access
Resource Type
journal article
Author(s)
Cornejo R.
Rios S.
Ochoa M.
Peña B.
Flores O.
Howard L.M.
Grijalva C.G.
Publisher(s)
John Wiley and Sons Inc
Abstract
Background: We assessed the prevalence and incidence of SARS-CoV-2 infections in a prospective study of households in Lima, Peru. Methods: Households with a child, a young adult 18–50 years, and an adult age >50 years in peri-urban Lima were followed with twice-a-week household visits during a 2-month period. Nasal swabs and saliva specimens were collected twice weekly, and nasopharyngeal swabs were collected weekly from each participant, regardless of symptoms. Laboratory-confirmed SARS-CoV-2 infection was defined by two RT-PCR tests from any of the collected specimens within a week. Blood samples collected at enrollment and end of follow-up were tested with rapid serological tests. We calculated the prevalence and incidence of laboratory-confirmed SARS-CoV-2 infections. Results: We enrolled 132 participants from 44 households: 44 children, 44 young adults, and 44 older adults. A total of 13 SARS-CoV-2 infections were detected in eight households, for an overall period prevalence of 9.85% (95% confidence interval [CI]: 5.35–16.25). Most (61.54%) infections were symptomatic. Eight of 11 (72.73%) SARS-CoV-2 detections corresponded to the Lambda variant. During 218.79 person-months at risk of follow-up, there were six new SARS-CoV-2 infections detected (2.74 per 100 person-month, 95% CI: 1.25–6.04). At enrollment, 59 of 128 participants tested had positive SARS-CoV-2 IgG serology (46.09%, 95% CI: 37.25–55.12). Five of six new infections occurred among participants with negative baseline serology. Conclusions: We demonstrated high incidence of SARS-CoV-2 infections in households, especially among subjects without evidence of prior infection, most of them not detected by the Ministry of Health system.
Start page
386
End page
394
Volume
16
Issue
3
Language
English
OCDE Knowledge area
Sistema respiratorio
Enfermedades infecciosas
Subjects
Scopus EID
2-s2.0-85121708237
PubMed ID
Source
Influenza and other Respiratory Viruses
ISSN of the container
17502640
Sponsor(s)
Funds were provided to the Institution, not to the authors. CFL is a member of WHO COVID‐19 vaccine effectiveness working group and WHO Product Development Advisory Group. CGG reports consultancy fees from Pfizer, Merck, and Sanofi‐Pasteur and grants from Campbell Alliance/Syneos Health, CDC, NIH, the Food and Drug Administration, AHQR, and Sanofi, outside the submitted work. LMH reports grant funding from the Infectious Disease Society of America Education and Research Fund supported by Pfizer and from NIH, outside the submitted work.
The authors would like to express their appreciation to the participating household members that were able to provide us with the high number of laboratory samples provided in this intense surveillance study. Also, to our field team, drivers, and laboratory personnel that worked hard to get the job done. To Mrs. Edda Franco for her editorial help in reviewing this manuscript. And to the funders that made possible the conduct of this study. This work is supported by Consejo Nacional de Ciencia y Tecnología CONCYTEC PROCIENCIA, Lima, Peru (contract no. 082‐2020); Vanderbilt University Medical Center, Nashville, TN, USA; and Instituto de Investigación Nutricional, Lima, Peru.
Sources of information:
Directorio de Producción Científica
Scopus